Therefore, rGRA6Nt is a novel protein adjuvant that has an unique activity to selectively activate production of both IFN-γ and IL-18 by innate immune cells to potently activate cancer-specific CD8+ cytotoxic T cells and IFN-γ production by both CD4+ and CD8+ T cells. Here, CD8A is linked to cancer.